Reality Check? Granules Moves Out Of China JV
Indian firm Granules is exiting its long-standing joint venture for ibuprofen API in China against the backdrop of evolving pollution control norms and the need for growing expenditure there, while emerging supply options have reduced the need for a local JV.
You may also be interested in...
Qpex licenses rights to its antibiotic portfolio in China to Brii Biosciences. Moberg and DongKoo partner on commercialization of onychomycosis therapy in Korea.
A recent trade group report points to a rising and alarming "Buy China" trend in procurement rounds in the country. Although largely in medical device bidding, it may potentially affect the pharma sector, an analysis from the recent “4+7” centralized bidding scheme show.
Ajinomoto Bio-Pharma Services has announced it is buying out partner Granules India from an API manufacturing joint-venture based in southern India as the company seeks to integrate its small- and large-molecule businesses and provide more seamless customer service.